Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease

被引：0
作者：
Hiroko Iijima
Toshifumi Tada
Mariko Hashimoto
Takashi Nishimura
Masato Kiriki
Akiko Higashiura
Aya Iwasaki
Michino Honda
Yasuyuki Nagasawa
Koichiro Yamakado
机构：
[1] Hyogo Medical University,Division of Gastroenterology and Hepatology, Department of Internal Medicine
[2] Hyogo Medical University,Ultrasound Imaging Center
[3] Japanese Red Cross Society Himeji Hospital,Department of Internal Medicine
[4] Hyogo Medical University,Department of Radiologic Technology
[5] Hyogo Medical University,Department of General Internal Medicine
[6] Hyogo Medical University,Department of Radiology
来源：
Journal of Medical Ultrasonics | 2023年 / 50卷
关键词：
Autosomal dominant polycystic kidney disease; Ultrasonography; Total kidney volume; Tolvaptan;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：81 / 87
页数：6
相关论文
共 55 条
[1]  
Spithoven EM(2014)Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival–an analysis of data from the ERA-EDTA registry Nephrol Dial Transpl 29 iv15-iv25
[2]  
Kramer A(2016)US renal data system 2015 annual data report: epidemiology of kidney disease in the United States Am J Kidney Dis 369 1287-1301
[3]  
Meijer E(2007)Autosomal dominant polycystic kidney disease Lancet 66 564-576
[4]  
Saran R(2015)Total kidney volume in autosomal dominant polycystic kidney disease: a biomarker of disease progression and therapeutic efficacy Am J Kidney Dis 26 160-172
[5]  
Li Y(2015)Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials J Am Soc Nephrol 7 479-486
[6]  
Robinson B(2012)Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 88 17-27
[7]  
Torres VE(2015)Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference Kidney Int 31 337-348
[8]  
Harris PC(2016)Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and european renal best practice Nephrol Dial Transpl 4 2054358117695784-244
[9]  
Pirson Y(2017)Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: a Canadian expert consensus Can J Kidney Health Dis 31 237-50
[10]  
Alam A(2011)Imaging approaches to patients with polycystic kidney disease Semin Nephrol 70 43-470
123456